JP6494527B2 - 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 - Google Patents

肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 Download PDF

Info

Publication number
JP6494527B2
JP6494527B2 JP2015557089A JP2015557089A JP6494527B2 JP 6494527 B2 JP6494527 B2 JP 6494527B2 JP 2015557089 A JP2015557089 A JP 2015557089A JP 2015557089 A JP2015557089 A JP 2015557089A JP 6494527 B2 JP6494527 B2 JP 6494527B2
Authority
JP
Japan
Prior art keywords
pneumococcal
antigen
polypeptide
cells
immunogenic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015557089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016509011A5 (https=
JP2016509011A (ja
Inventor
リチャード マリー
リチャード マリー
インジェ ルー
インジェ ルー
ファン チャン
ファン チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2016509011A publication Critical patent/JP2016509011A/ja
Publication of JP2016509011A5 publication Critical patent/JP2016509011A5/ja
Priority to JP2019039100A priority Critical patent/JP6916828B2/ja
Application granted granted Critical
Publication of JP6494527B2 publication Critical patent/JP6494527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2015557089A 2013-02-07 2014-02-07 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 Active JP6494527B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019039100A JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762062P 2013-02-07 2013-02-07
US61/762,062 2013-02-07
PCT/US2014/015254 WO2014124228A1 (en) 2013-02-07 2014-02-07 Protein antigens that provide protection against pneumococcal colonization and/or disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019039100A Division JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Publications (3)

Publication Number Publication Date
JP2016509011A JP2016509011A (ja) 2016-03-24
JP2016509011A5 JP2016509011A5 (https=) 2017-03-09
JP6494527B2 true JP6494527B2 (ja) 2019-04-03

Family

ID=51300148

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557089A Active JP6494527B2 (ja) 2013-02-07 2014-02-07 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
JP2019039100A Active JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019039100A Active JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原

Country Status (7)

Country Link
US (3) US11576958B2 (https=)
EP (2) EP2953638B1 (https=)
JP (2) JP6494527B2 (https=)
AU (2) AU2014214844B2 (https=)
CA (2) CA2900008C (https=)
ES (1) ES2959258T3 (https=)
WO (1) WO2014124228A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
EP4488286A3 (en) 2016-03-31 2025-04-02 Pogona, Llc Saccharide-polypeptide conjugate compositions and methods of use thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
PT3585803T (pt) * 2017-02-24 2025-12-22 Merck Sharp & Dohme Formulações de vacina pneumocócica conjugada
AU2018243910B2 (en) 2017-03-28 2025-04-10 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
US10525119B2 (en) 2017-03-31 2020-01-07 Boston Medical Center Corporation Methods and compositions using highly conserved pneumococcal surface proteins
US12090198B2 (en) * 2017-05-22 2024-09-17 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis
WO2018237221A1 (en) 2017-06-23 2018-12-27 Nosocomial Vaccine Corporation IMMUNOGENIC COMPOSITIONS
PT3678654T (pt) 2017-09-07 2024-08-05 Merck Sharp & Dohme Llc Polissacáridos pneumocócicos e sua utilização em conjugados imunogénicos de polissacárido-proteína transportadora
US12257295B2 (en) 2017-10-04 2025-03-25 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
GB201807380D0 (en) 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
EP3847246A1 (en) * 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
JP7535791B2 (ja) * 2018-09-12 2024-08-19 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌融合タンパク質ワクチン
IL281204B2 (en) * 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
KR20220018939A (ko) * 2020-08-07 2022-02-15 (주)셀트리온 폐렴구균 다당류-세포벽 유래 물질 접합체를 포함하는 면역원성 조성물
IL326005A (en) 2021-09-09 2026-03-01 Affinivax Inc Multivalent pneumococcal vaccines
CN120826235A (zh) * 2023-03-16 2025-10-21 艾芬尼维克斯公司 免疫原性组合物
WO2024229176A1 (en) 2023-05-04 2024-11-07 Affinivax, Inc. Rhizavidin variants
WO2025193903A1 (en) 2024-03-15 2025-09-18 Affinivax, Inc. Pneumococcal polysaccharide compositions and uses thereof

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1502774A (en) 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
CA1299099C (en) 1986-03-06 1992-04-21 Paul Richard Wood In vitro assay for detecting cell-mediated immune responses
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8906795D0 (en) 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
JPH0372423A (ja) 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5674698A (en) 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
DE69738597T2 (de) 1996-02-09 2008-07-24 Glaxosmithkline Biologicals S.A. Vakzine gegen das varicella zostervirus produkt von gen 63
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DE69826851T2 (de) 1997-04-24 2005-02-10 Henry M. Jackson Foundation For The Advancement Of Military Medicine Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
DE69935986D1 (de) * 1998-07-27 2007-06-14 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
CN1318103A (zh) * 1998-07-27 2001-10-17 微生物技术有限公司 肺炎链球菌的核酸和蛋白质
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2322306T3 (es) 1998-12-21 2009-06-18 Medimmune, Inc. Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas.
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
GB9928678D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Streptococcus pneumoniae antigens
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
AU9475001A (en) 2000-09-26 2002-04-08 Hybridon Inc Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP4360906B2 (ja) 2001-09-14 2009-11-11 サイトス バイオテクノロジー アーゲー ウィルス様粒子によって誘導される免疫応答を高めるための、抗原提示細胞のインビボでの活性化
WO2003044185A2 (en) 2001-11-21 2003-05-30 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20060121058A1 (en) 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
ES2451620T3 (es) 2002-11-07 2014-03-28 Synergy America, Inc. Composiciones y métodos destinados a tratar o prevenir la infección neumocócica
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2333114A1 (en) 2003-04-15 2011-06-15 Intercell AG S. pneumoniae antigens
CA2524853A1 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
AU2004281634B2 (en) 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
US20050112139A1 (en) 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20050226899A1 (en) 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
JP2008509682A (ja) 2004-08-18 2008-04-03 ガヴァナーズ オブ ザ ユニヴァーシティー オブ アルバータ Ｙｅｂｆを利用するタンパク質の製造方法
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2592627C (en) 2005-01-20 2014-02-25 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
WO2006084466A2 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
NZ598367A (en) 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
JP5564181B2 (ja) 2005-12-08 2014-07-30 シルワン，ハヴァル 免疫刺激組成物および方法
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
WO2007098186A2 (en) 2006-02-22 2007-08-30 Novavax, Inc. Adjuvant and vaccine compositions
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
WO2007150020A1 (en) 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
NZ575901A (en) 2006-09-12 2012-04-27 Alphavax Inc Alphavirus replicon particles matched to protein antigens as immunological adjuvants
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
WO2008152448A2 (en) 2006-12-21 2008-12-18 Emergent Product Development Uk Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
JP5714230B2 (ja) 2007-01-31 2015-05-07 フェネックス インコーポレイテッド 発現上昇のための細菌リーダー配列
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
CA2683748C (en) 2007-04-13 2016-02-16 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2176291A1 (en) 2007-08-10 2010-04-21 Wacker Chemie AG Expression of full length igg and secretion into the culture medium of prokaryotic cells
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US20090068288A1 (en) 2007-09-07 2009-03-12 Wayne Kruger Topical antiseptic veterinary solution
US9125863B2 (en) 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
EP2379106A4 (en) 2008-12-17 2012-06-13 Genocea Biosciences Inc ANTIGENS OF CHLAMYDIAS AND USES THEREOF
CN102712680B (zh) 2008-12-24 2016-06-22 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
SG10201403702SA (en) 2009-06-29 2014-09-26 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
CN102648003B (zh) 2009-10-09 2016-01-13 儿童医疗中心有限公司 选择性裂解的全细胞疫苗
EP2335721A1 (en) 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
US20110159040A1 (en) 2009-12-30 2011-06-30 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
US20130115230A1 (en) 2010-04-30 2013-05-09 Augmenta Biologicals, Llc Delivery proteins
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
US9393294B2 (en) 2011-01-20 2016-07-19 Genocea Biosciences, Inc. Vaccines and compositions against Streptococcus pneumoniae
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
CA2897020A1 (en) 2012-01-20 2013-07-25 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
JP6494527B2 (ja) 2013-02-07 2019-04-03 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
JP7535791B2 (ja) 2018-09-12 2024-08-19 ザ チルドレンズ メディカル センター コーポレーション 肺炎球菌融合タンパク質ワクチン
IL281204B2 (en) 2018-09-12 2025-07-01 Affinivax Inc Multivalent pneumococcal vaccines

Also Published As

Publication number Publication date
US20250114443A1 (en) 2025-04-10
JP2019108375A (ja) 2019-07-04
EP4272750A2 (en) 2023-11-08
ES2959258T3 (es) 2024-02-22
EP2953638A1 (en) 2015-12-16
US11576958B2 (en) 2023-02-14
EP2953638A4 (en) 2016-08-03
AU2014214844B2 (en) 2017-12-14
AU2018201768A1 (en) 2018-04-05
CA2900008A1 (en) 2014-08-14
US12083173B2 (en) 2024-09-10
CA3247431A1 (en) 2026-03-02
AU2014214844A1 (en) 2015-08-13
AU2018201768B2 (en) 2020-03-12
WO2014124228A1 (en) 2014-08-14
EP2953638B1 (en) 2023-07-05
CA2900008C (en) 2025-10-07
JP2016509011A (ja) 2016-03-24
JP6916828B2 (ja) 2021-08-11
US20230081705A1 (en) 2023-03-16
EP4272750A3 (en) 2024-01-24
US20150374811A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
US12083173B2 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
US11207375B2 (en) Vaccines and compositions against Streptococcus pneumoniae
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
JP2013520487A (ja) 免疫原性タンパク質および組成物
CN109069424B (zh) 脂质体疫苗
US20090252756A1 (en) Protein-based streptococcus pneumoniae vaccines
WO2024259229A2 (en) Fusion proteins generating protective antibodies and protective th17 responses for pseudomonas aeruginosa
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
TW201726164A (zh) 脂質體疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180723

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190305

R150 Certificate of patent or registration of utility model

Ref document number: 6494527

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250